Bloom syndrome protein (BLM) is one of five human RecQ helicases which maintain genomic stability. Interaction of BLM with replication protein A (RPA) stimulates the DNA unwinding ability of BLM. The interaction is expected to be crucial in the DNA damage response. Although this stimulation of BLM by RPA is of particular importance in cancer cells, the precise binding surfaces of both proteins are not well understood. In this study, we show by fluorescence polarisation anisotropy that both acidic surface peptides of BLM specifically bind to the RPA70N domain of RPA. Our NMR analysis and docking models show that the basic cleft region of RPA70N is the binding site for both peptides and that the acidic peptide/basic cleft interaction governs RPA-BLM binding.
Edited by Christian Griesinger
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Keywords: BLM; Bloom syndrome; NMR; protein-protein interaction; replication protein A Replication protein A (RPA) is the eukaryotic singlestranded (ss) DNA-binding protein involved in DNA metabolism functions such as replication, repair, and recombination [1] [2] [3] . Human RPA consists of three subunits: RPA70, RPA32 and RPA14 (Fig. 1A) . RPA is a modular protein and contains 6 oligonucleotide binding (OB) folds. Among these OB-folds, DNA binding domains (DBDs) A, B and C (in RPA70) and DBD-D (in RPA32) function as the main ssDBDs [4, 5] . DBD-F in the N-terminal part of RPA70 (RPA70N) is known to be involved in protein-protein interactions with various DNA damage response proteins such as ATRIP, RAD9, MRE11 and p53 [6, 7] . Recently, it has been revealed that large T antigen, a helicase protein of Simian virus 40 (SV40), human DNA helicase B, and Ewing tumour-associated antigen 1 (ETAA1) also physically interact with human RPA70N [8] [9] [10] . In each case, the basic cleft of RPA70N between loops L12 and L45 is the binding surface for acidic surface peptides (Fig. 1B) .
Bloom syndrome protein (BLM), 1 of 5 human RecQ helicases, contributes to genomic stability via its helicase activity [11, 12] . It has been revealed that BLM physically and functionally interacts with RPA, and the N-terminal segment of BLM (1-447) was identified as the binding region for RPA [13] (Fig. 1A) . Conversely, the BLM binding region of RPA was generally identified as RPA70 [13, 14] . Interestingly, a BLM helicase construct which lacked the RPA interaction site showed reduced unwinding activity for long DNA substrates [13] . Also, a single-molecule F€ orster resonance energy transfer study showed that RPA promotes the reinitiation of stalled DNA unwinding by BLM helicase [15] . These findings imply that the direct BLM-RPA interaction is essential for the stimulation by RPA of helicase-catalysed DNA unwinding. In particular, it is known that Sgs1, the yeast homologue of BLM, interacts with Rpa70 in yeast and has a crucial role in checkpoint signaling by recruiting Rad53 to regions of ssDNA at stalled replication forks [16] . BLM is expected to have a similar role in human cells by interacting with RPA [17] . Considering the importance of checkpoint signaling in cancer cells, it is necessary to understand the details of the BLM-RPA interaction for developing novel anticancer strategies.
Previous research showed that the acidic region of Werner syndrome protein (WRN), another human RecQ helicase, is essential for its interaction with RPA [13] . By analogy to the WRN-RPA interaction, it has been suggested that the acidic surface peptides of BLM are crucial for its binding to RPA70 [13] . Based on these findings, and considering sequences of other RPA-interacting proteins such as ATRIP, MRE11, and p53, we chose two acidic surface peptides in the N-terminal region of BLM for examining its binding to RPA: 153-165 (DWDDMDDFDTSET) and 290-301 (EFDDDDYDTDFV). Conversely, RPA70N is the primary candidate for BLM binding, because it is involved in various protein-protein interactions as described above. We also assessed the RPA70A domain as a potential BLM binding site, because this region is necessary for WRN binding [13, 18] .
To investigate the RPA-BLM interaction in detail, we analysed the chemical shift perturbations in RPA70N and RPA70A during titration with the BLM peptides. We found that both peptides specifically bound to RPA70N, but not RPA70A. We mapped the binding surfaces of the BLM peptides on RPA70N and also determined the dissociation constants for both peptides using fluorescence polarisation anisotropy (FPA). Our analysis and docking models provide detailed information about the BLM-RPA interaction and give insights into the common acidic peptide-basic cleft interaction mediated by RPA70N.
Materials and methods

Sample preparation
The fluorescein isothiocyanate (FITC)-labelled BLM [153] [154] [155] [156] [157] [158] [159] [160] [161] [162] [163] [164] [165] (FITC-aca-DWDDMDDFDTSET) and BLM 290-301 (FITCaca-EFDDDDYDTDFV) peptides were purchased from AnyGen (Gwangju, Korea). The FITC-BLM 153-165 and FITC-BLM 290-301 peptides were purified using HPLC to 97.5% and 95.4% purity respectively. Unlabelled BLM [153] [154] [155] [156] [157] [158] [159] [160] [161] [162] [163] [164] [165] and BLM 290-301 were also purchased from AnyGen and purified with the same method. RPA70N (residues 1-120) and RPA70A (residues 181-304) constructs were cloned into a pET15b vector and transformed into BL21(DE3) cells. The proteins were overexpressed and purified as described previously [19, 20] . 
NMR experiments
H-
15
N HSQC experiments were performed using a Bruker 900 MHz NMR spectrometer equipped with a cryogenic probe (KBSI, Ochang). The electrostatic surface of RPA70N is shown. Electrostatics calculations were performed with PDB2PQR [36] and visualised with PyMOL [27] . Positively charged (+8 kT/e in blue) and negatively charged (À8 kT/e in red) amino acids are marked.
the program Topspin and analysed with the program Sparky [21] . Averaged chemical shift perturbations (Dd avg ) were calculated with equation 1,
where Dd H and Dd N are the chemical shift differences in the amide proton and nitrogen resonances, respectively. Residues which have Dd avg more than one or two standard deviations above the average are considered as significantly perturbed one. We used the amide chemical shifts of RPA70N and RPA70A that were published previously [22, 23] .
Fluorescence polarisation anisotropy experiments
We used FITC labels with 6-aminohexanoic acid spacer on the N-terminal of both peptides for fluorescence polarisation assays. FITC is widely used fluorescence dye and known to contribute partial negative charges at neutral pH. The effect of FITC labeling was previously tested with FITC labelled ATRIP peptides and RPA70N [20] . The study showed the labelled and unlabelled peptides have identical binding mode while the FITC labeling had a slightly higher binding affinity to RPA70N. On the basis of this, we thought that FITC labeling in our system does not severely alter the binding mode of peptides. In this study, increasing concentrations (0-200 lM) of RPA70N (or RPA70A) in 200 lL of assay buffer (50 mM HEPES, 100 mM NaCl, 2 mM DTT, pH 7.5) containing 5% DMSO and 50 nM FITC-BLM peptides were mixed on a shaker for 15 min and incubated for 1 h at room temperature. Corning 96-well black plates (Polystyrene, non-treated flat bottom) were used. The FPA intensities were measured at an excitation wavelength of 485 nm and an emission wavelength of 528 nm using the Cytation5 (BioTek, Gwangju, South Korea) and GENE5 software (GIST, Gwangju). The emission polarisation anisotropy was determined with reference to a previous report [20] . Emission anisotropy data were analysed using GRAPHPAD PRISM version 7.01 for Windows (GraphPad Software, La Jolla, CA, USA, www.graphpad.c om). Anisotropy values were plotted against an x-axis of increasing concentrations of RPA70N or RPA70A, and a 'saturation one-site' fitting model was used to determine the dissociation constant (K d ). An FPA competition assay was performed to compare the interaction of RPA70N with FITC-BLM 153-165 with that of a known protein interaction inhibitor. We chose 3,3 0 ,5,5 0 -tetraiodothyroacetic acid as the RPA70N inhibitor based on a previous report [20] . Increasing concentrations of 3,3 0 ,5,5 0 -tetraiodothyroacetic acid (0-500 lM) were added to 6 lM of RPA70N and 500 nM of FITC-BLM 153-165 in 200 lL of assay buffer containing 5% DMSO. The contents were mixed on the shaker for 15 min and incubated for 1 h at room temperature. The IC 50 value was determined using the log[Inhibitor] vs. response - 
Docking
Modelling of the RPA70N-BLM peptide complexes was performed on the CABS-dock Web server [25] . We used the crystal structure of RPA70N (RCSB ID: 2B29) as the starting coordinates, and coordinates for the peptides were generated by the server based on each peptide sequence [7] . Fifty simulation cycles and default parameters were used for the modelling. After flexible docking (10 000 models generation) and initial filtering, the filtered 1000 models are grouped into clusters in the k-medoid clustering procedure. Detailed methods were described previously [26] . The highest cluster density model of each simulation was further analysed. The binding surface was defined as pairs of peptide/protein residues closer than 4.5 A in the complex. The docked structures were visualised with Pymol [27] . To validate the docking simulation, we tested the same default parameters of CABSdock simulation for RPA70N-p53 complex. Also we performed HADDOCK simulation for RPA70N-BLM 153-165 complex. HADDOCK requires binding sites (active residues) and the coordinates of the protein and the peptide. For the RPA70N side, R31, R43, S55, M57, A59, T60, N85, V93, Y118 and E120 were used as active residues based on the NMR data. For the BLM 153-165 , two aromatic residues (W154 and F160) were chosen based on the binding affinity test of ATRIP peptides to RPA70N [28] . We used the crystal structure of RPA70N (RCSB ID: 2B29) as the starting coordinate and the coordinate of BLM 153-165 from model 1 of CABS-dock results. We used HADDOCK 2.2 web version (http://milou.science.uu.nl/services/HADDOCK2.2/) with the default setting [29] . Finally, we tested pep-ATTRACT server for both RPA70N-BLM 153-165 and RPA70N-BLM 290-301 complexes with the default setting (http://biose rv.rpbs.univ-paris-diderot.fr/services/pepATTRACT/) [30] .
Results
Chemical shift perturbation of RPA70N upon binding to BLM peptides (Fig. 2C) . S55, T60, and E120 of RPA70N shifted more than two standard deviations above the average in the presence of both peptides. Interestingly, most of the shifted peaks except R92 showed the same direction of change with both peptides (Fig. 2D,E) . The residues perturbed more than one standard deviation by both peptides (R31, R43, S55, M57, A59, T60, N85, V93, Y118 and E120) were used to map a common binding surface on the crystal structure of RPA70N [7] (Fig. 2F ). This surface is the same as previously defined binding surfaces of RPA70N for p53 [7] , ATRIP, RAD9, MRE11 [6] , SV40 [8] and ETAA1 [10] . This implies that both BLM peptides use the same binding surface as other RPA70N-interacting proteins.
Chemical shift perturbation of RPA70A upon binding to BLM peptides Figures 3A,B show the chemical shift changes of RPA70A upon addition of BLM 153-165 and BLM 290-301 respectively. Overall, the amplitudes of Dd avg were much smaller than in the case of RPA70N with BLM peptides. The maximum Dd avg was less than 0.06, while that of RPA70N was around 0.15. This implies that the binding of both peptides to RPA70A is weaker than the binding to RPA70N. Cross-peaks of N214, E290 and H293 showed relatively prominent chemical shift changes in the presence of both peptides. These residues are near the ssDNA-binding surface of RPA70A. However, magnitudes of Dd avg by ssDNA were significantly larger with a lM order of K d [31] . It is expected that the binding affinity of the peptides is much weaker than that of ssDNA. This implies that both peptides have a binding preference for the RPA70N domain over the RPA70A domain. Figure 4A shows the fluorescence anisotropy of the FITC-labelled BLM peptides in the presence of increasing concentrations of RPA70N. Via curve fitting, the K d of the RPA70N-BLM 153-165 complex was determined to be 5.76 AE 0.86 lM, and the K d of the RPA70N-BLM 290-301 complex was determined to be 13.5 AE 2.4 lM. The binding of the peptides to RPA70N produced a typical hyperbolic binding isotherm. In contrast, RPA70A did not specifically bind to either BLM peptide (Fig. 4B) . The anisotropy values of both FITC-labelled peptides with increasing concentrations of RPA70A were not saturated and could not be fitted. This result is consistent with our NMR data, which showed that only RPA70N exhibited significant chemical shift changes upon titration of the BLM peptides. Figure 4C shows the fluorescence anisotropy of FITC-BLM 153-165 in the presence of increasing concentrations of 3,3 0 ,5,5 0 -tetraiodothyroacetic acid, which is known to inhibit RPA70N-ATRIP complex formation [20] . The decrease in anisotropy of FITC-BLM 153-165 at higher concentrations indicates that the inhibitor and the BLM peptide compete for the same binding surface on RPA70N. This result confirmed that FITC-BLM 153-165 interacts with RPA70N via the same binding surface as other RPA-interacting proteins. The IC 50 value of the inhibitor was determined to be 40.63 AE 1.17 lM, and the K d value was determined to be 17.77 AE 0.52 lM. These values were comparable to those published in a previous study [20] .
Fluorescence polarisation anisotropy assays
Docking model of the RP70N-BLM peptide complex
To investigate the details of the RPA70N-BLM peptide binding surfaces, we performed docking simulations. The docking for the RPA70N-BLM 153-165 complex generated 10 clusters with a combined 1000 models. The details of structural clustering are shown in Table S1 . The first cluster contained 114 structures with a 2.82 A average cluster RMSD (an average pairwise Ca RMSD value between models grouped in a cluster). All the major clusters (number of elements ≥90, clusters 1 to 7) consist of structural models with an extended peptide conformation without any secondary structure. The predicted peptide binding site in six of the seven major clusters was the basic cleft region (Fig. 5A-C) . However, the orientations of the bound peptides were mixed. In models 1, 2 and 5, the peptides were oriented parallel to the modified ATRIP peptide bound to RPA70N (RCSB ID: 4NB3, [28] ) while the peptide orientation in models 3, 4 and 6 was reversed (Fig. 5A,B) . In model 1, W154 of the BLM 153-165 peptide was in close proximity to P40, R41, Y52, M57, L58, A59, T60 and N63 of RPA70N. Basic residues of RPA70N (R41, R43, and R91) interacted with acidic residues of BLM peptides (D159 and E164). The binding interfaces of the complex are composed of residues with significant chemical shift changes (Dd avg ≥ average + 1r) and their neighbours (Fig. 5D) . Similar results were observed when modelling the RPA70N-BLM 290-301 complex. The details of structural clustering are shown in Table S2 . The first cluster contained 149 structures with an average cluster RMSD of 2.98
A. Like the BLM 153-165 peptide, this peptide was in an extended, unstructured conformation in the average complex structure of all major clusters (number of elements ≥ 100, clusters 1 to 6). The representative structures of each major cluster had the peptide binding to the basic cleft of RPA70N, while the binding orientations were mixed. Models 1, 2, 3 and 4 had the BLM peptide antiparallel to the modified ATRIP peptide bound to RPA70N (RCSB ID: 4NB3, [28] ) (Fig. 5E) . Models 5 and 6 had the BLM peptide in the same orientation as the modified ATRIP peptide (Fig. 5F) . In model 1, most residues of BLM 290-301 were involved in RPA70N binding. Basic residues of RPA70N (R31, R41, R43, R91 and R92) were near to E290, D292, D294, D295 and D297 of BLM (Fig. 5G) . Both BLM peptides passed through the two loops (L12 and L45) and had similar interactions with RPA70N (Fig. S1A) . Detailed interactions per residue of both peptides are shown in Fig. S1B .
Validation of the docking simulation
To validate our docking simulation, we performed the CABS-dock running for RPA70N-p53 33-60 complex with default parameters. CABS-dock successfully predicted the secondary structure of p53 33-60 using PSIPRED. Two helices were correctly predicted (Fig. 6A) . The final models also have at least one helical conformation. The details of structural clustering are shown in Table S3 . We examined cluster 1 to 6. As shown in Fig. 6B-I , the main binding site of RPA70N are located in the basic cleft region. However, the helix conformation and orientation are various. Compared to experimentally known RPA70N-p53 33-60 structure, model 5 (Fig. 6G) is the best-matched one. Model 1 used the same binding interfaces with model 5, but its orientation of H2 is opposite. The data showed that the CABS-dock could recover helical conformation without previous knowledge but the orientation could be mixed.
For RPA70N-BLM 153-165 complex, we also performed HADDOCK simulation. HADDOCK clustered 190 structures in four clusters, which represent 95.0% of the water-refined models HADDOCK generated. Except cluster 1 that has 169 structures, other three clusters have z-score as 0 and cluster sizes are 12, 5 and 4 respectively. Details of Cluster 1 are shown in Table S4 . The four best structures of cluster 1 are shown in Fig. 7A ,B. The peptide binding region is consistent with the basic cleft region, but orientations are not converged.
Finally, we tested pep-ATTRACT server for both complexes. The 50 lowest energy models of RPA70N-BLM 153-165 complex and RPA70N-BLM 290-301 complex are shown in Fig. 7C ,D. The peptide conformations are all extended. The binding surfaces include the basic cleft region but the other areas are also predicted as the possible binding sites.
Discussion
In this study, we showed that two acidic segments (153-165 and 290-301) of the N-terminal domain of BLM specifically bind to RPA70N. Our NMR data indicate that residues in the basic cleft of RPA70N were perturbed by both peptides with similar magnitudes. Because RPA70 is a large protein with multiple domains, it is worth defining the RPA70N domain specifically as the BLM binding region. Interestingly, RPA70A, the major ssDNA binding domain, shares a common OB-fold with RPA70N, and Rad51, which contains several acidic amino acids, binds to RPA70A [32] . However, in our study, both BLM peptides showed a clear preference for binding RPA70N over RPA70A. This suggests that BLM can interact with RPA via the RPA70N domain while the other domains of RPA protect ssDNA. Stimulation of BLM activity by RPA may be mediated through this protein-protein interaction.
The surface of RPA70N to which BLM binds has multiple interaction partners, including DNA damage response proteins such as ATRIP and ETAA1 [6, 10] . A sequence comparison of the two BLM peptides with the primary binding sites of other RPA-binding proteins confirmed that those sequences commonly have high acidic content and include several hydrophobic residues (Fig. 8) . It is known that F55 of ATRIP is critical for RPA binding [28] . In the BLM peptides, W154 of BLM 153-165 and F291 of BLM [290] [291] [292] [293] [294] [295] [296] [297] [298] [299] [300] [301] located in the position equivalent to F55 of ATRIP in its complex with RPA70N. This result suggests that the protein-protein interaction is not only mediated by electrostatic attraction but also by precisely tuned hydrophobic interactions. The negative charge and hydrophobicity of the BLM peptides are not localised within the peptide sequences. This could explain why both orientations of the RPA70N-bound peptides appeared in our docking simulations. Because of the importance of these RPA-protein interactions in the damage response system, inhibitors have been developed for potential anticancer drugs [28, [33] [34] [35] . We found that the K d s of the BLM peptide-RPA70N complexes are similar to that of the ATRIP-RPA70N complex [20] . Furthermore, 3,3 0 ,5,5 0 -tetraiodothyroacetic acid, which is a known competitor for the ATRIP binding site on RPA70N, can also inhibit the interaction of BLM 153-165 with RPA70N. These results suggest that protein interactions with RPA70N involve a common strategy and that the BLM-RPA interaction can be inhibited in the same way as other interactions.
Although the p53 peptide forms an amphipathic helix in the crystal structure of the p53/RPA70N complex [7] , the BLM-RPA docking models suggest that the BLM peptides do not form secondary structures. CD spectroscopy showed that the BLM peptides do not possess secondary structure in solution and that RPA binding does not induce the peptides to form secondary structures (Fig. S2 and Doc. S1). The BLM peptides' conformation is closer to that of a linked ligand which simultaneously bound to 'site 1 0 (near S55) and 'site 2' (near T60) in a previous study [34] . Our NMR data showed that both S55 and T60 experience prominent chemical shift perturbations upon binding to both BLM peptides. Furthermore, the docking models of the RPA70N-BLM complex support that the BLM peptides make contact with these two locations of RPA70N. In contrast, the p53 peptide does not make contact with the 'site 2' region of RPA70N. This comparison gives insight into how RPA-mediated protein-protein interaction can be modulated depending on the contact area on RPA70N.
Unlike other RPA70N-binding proteins studied previously, the N-terminal region of BLM contains at least two RPA70N binding sites that have a similar lM K d . However, although the RPA-binding affinities of the two BLM peptides that were used in this study are of the same order of magnitude, the RPA70N-BLM 153-165 had~2-fold higher binding affinity than the RPA70N-BLM 290-301 complex. Although we chose each peptide based on its sequence homology with other RPA70N-binding peptides, there is a possibility that the peptide length could affect the binding affinity. However, if the binding affinity difference is inherent, we can develop hypotheses regarding the RPA-BLM interaction. First, more than one RPA molecule may be able to interact with a BLM molecule simultaneously, with a preference for the site with higher affinity. For example, an RPA70N molecule binds first to the BLM 153-165 site, and a second RPA molecule can interact with the BLM 290-301 site. Each RPA-binding site could interact independently or cooperatively. In this study, we examined each site as a separate peptide because BLM (153-301) and (150-340) constructs that contain both binding site were not expressed in E.coli to assess how the two sites play their roles in RPA binding, further studies are required. Second, the RPA-binding sites might be specific for the pathway that both proteins are involved in or dependent upon the expression levels of both proteins in the cell. Our understanding of the actual mechanism of BLM activation by RPA is incomplete, so further research on RPA-BLM binding in vivo is necessary.
In summary, we have studied the interaction of RPA70N with two BLM peptides by NMR spectroscopy and FPA. Two acidic peptides of BLM specifically bound to RPA70N with micromolar affinities. We found that RPA-BLM binding is mediated by interaction of acidic surface peptides of BLM with the basic cleft of RPA70N, similar to the binding modes of other RPA-interacting proteins. Our study confirms that the basic cleft region of RPA70N could be considered as a ubiquitous target for the inhibition of protein-protein interactions in cancer cells.
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